HLS Therapeutics Inc is seeing a notable rise in its stock price, reflecting positive investor sentiment.
HLS Therapeutics Inc (HLS.TO) gained 2.56% today, closing at CA$4.00. This increase comes as the company expands its portfolio and strengthens its market presence in Canada.
Investor takeaway: Investors are reacting positively to HLS's recent developments, including the launch of new therapies, which may indicate a promising growth path for the company.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$120.65M
52W high
$5.76
52W low
$3.56
1W change
+5.41%
Beta
0.83
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 88.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.33
+88.0% Upside
Current Price
C$3.90
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
39.2%
Annualized
90-Day Vol
30.5%
Annualized
Trend (90d)
-49.7%
Annualized drift
90d Mean
C$3.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.68 | C$3.21 – C$4.21 |
| 60 trading days | C$3.46 | C$2.86 – C$4.20 |
| 90 trading days | C$3.27 | C$2.58 – C$4.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
HLS Therapeutics Inc sees a 2.56% increase in stock price today.
Advertisement
With a market capitalization of CA$120.6 million, HLS's stock performance today shows a growing interest in its innovative cardiovascular solutions.
Bull case
The recent approval and launch of NILEMDO™ could significantly enhance HLS's revenue, addressing a key need for patients who can't use traditional statin therapies. This new treatment is designed for those who struggle to meet their LDL-C goals with standard options, and the positive feedback from healthcare providers and patients is likely contributing to the stock's rise today.
Bear case
Despite the recent gains, HLS still faces hurdles, including a negative profit margin and the ongoing need for revenue growth to keep investor confidence high. The company must demonstrate financial improvement to maintain the momentum it has built.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
